-
公开(公告)号：US10010562B2
公开(公告)日：2018-07-03
申请号：US15033715
申请日：2014-11-03
发明人： Steven L. Colletti , Thomas J. Tucker , David M. Tellers , Boyoung Kim , Rob Burke , Kathleen B. Calati , Matthew G. Stanton , Rubina G. Parmar , Jeffrey G. Aaronson , Weimin Wang
IPC分类号： A61K31/713 , C12N15/113 , C07H15/203 , A61K31/7125 , A61K38/10 , A61K38/16
CPC分类号： A61K31/7125 , A61K31/713 , A61K38/10 , A61K38/16 , C07K2319/10 , C12N15/111 , C12N15/113 , C12N15/87 , C12N2310/14 , C12N2310/351 , C12N2320/31
摘要： Disclosed herein is a method for inhibiting expression of a gene of a subject comprising administering (1) a composition comprising R-(L)a-(G)b; wherein R is an oligonucleotide selected from the group consisting of DNA, RNA, siRNA, and microRNA; L is a linker and each occurrence of L is independently selected from Table 3; G is a targeting ligand and each occurrence of G is independently selected from Table 4; each of a and b is independently 0, 1, 2, 3 or 4; and (2) a composition comprising (P)c-(L)d-(G)e; wherein P is a peptide and each occurrence of P is independently selected from Table 2; L is a linker and each occurrence of L is independently selected from Table 3; G is a targeting ligand and each occurrence of G is independently selected from Table 4; d is 0, 1, 2, 3, 4, 5 or 6; and each of c and e is independently 1, 2, 3, 4, 5 or 6. Compositions in (1) and (2) can be co-administered or sequentially administered.
-
公开(公告)号：US20170189441A1
公开(公告)日：2017-07-06
申请号：US15033715
申请日：2014-11-03
申请人： Steven L. COLLETTI , Thomas J. TUCKER , David M. TELLERS , Boyoung KIM , Rob BURKE , Kathleen B. CALATI , Matthew G. STANTON , Rubina G. PARMAR , Jeffrey G. AARONSON , Weimin WANG , MERCK SHARP & DOHME CORP.
发明人： Steven L. Colletti , Thomas J. Tucker , David M. Tellers , Boyoung Kim , Rob Burke , Kathleen B. Calati , Matthew G. Stanton , Rubina G. Parmar , Jeffery G. Aaronson , Weimin Wang
IPC分类号： A61K31/7125 , A61K38/10 , A61K38/16 , A61K31/713
CPC分类号： A61K31/7125 , A61K31/713 , A61K38/10 , A61K38/16 , C07K2319/10 , C12N15/111 , C12N15/113 , C12N15/87 , C12N2310/14 , C12N2310/351 , C12N2320/31
摘要： Disclosed herein is a method for inhibiting expression of a gene of a subject comprising administering (1) a composition comprising R-(L)a-(G)b; wherein R is an oligonucleotide selected from the group consisting of DNA, RNA, siRNA, and microRNA; L is a linker and each occurrence of L is independently selected from Table 3; G is a targeting ligand and each occurrence of G is independently selected from Table 4; each of a and b is independently 0, 1, 2, 3 or 4; and (2) a composition comprising (P)c-(L)d-(G)e; wherein P is a peptide and each occurrence of P is independently selected from Table 2; L is a linker and each occurrence of L is independently selected from Table 3; G is a targeting ligand and each occurrence of G is independently selected from Table 4; d is 0, 1, 2, 3, 4, 5 or 6; and each of c and e is independently 1, 2, 3, 4, 5 or 6. Compositions in (1) and (2) can be co-administered or sequentially administered.
-
公开(公告)号：US20190015442A1
公开(公告)日：2019-01-17
申请号：US15974135
申请日：2018-05-08
发明人： Steven L. Colletti , Thomas J. Tucker , David M. Tellers , Boyoung Kim , Rob Burke , Kathleen B. Calati , Matthew G. Stanton , Rubina G. Parmar , Jeffrey G. Aaronson , Weimin Wang
IPC分类号： A61K31/7125 , C12N15/113 , C12N15/87 , A61K38/16 , A61K38/10 , A61K31/713 , C12N15/11
CPC分类号： A61K31/7125 , A61K31/713 , A61K38/10 , A61K38/16 , C07K2319/10 , C12N15/111 , C12N15/113 , C12N15/87 , C12N2310/14 , C12N2310/351 , C12N2320/31
摘要： Disclosed herein is a method for inhibiting expression of a gene of a subject comprising administering (1) a composition comprising R-(L)a-(G)b; wherein R is an oligonucleotide selected from the group consisting of DNA, RNA, siRNA, and microRNA; L is a linker and each occurance of L is independently selected from Table 3; G is a targeting ligand and each occurance of G is independently selected from Table 4; each of a and b is independently 0, 1, 2, 3 or 4; and (2) a composition comprising (P)c-(L)d-(G)e; wherein P is a peptide and each occurance of P is independently selected from Table 2; L is a linker and each occurance of L is independently selected from Table 3; G is a targeting ligand and each occurance of G is independently selected from Table 4; d is 0, 1, 2, 3, 4, 5 or 6; and each of c and e is independently 1, 2, 3, 4, 5 or 6. Compositions in (1) and (2) can be co-administered or sequentially administered.
-
公开(公告)号：US10239957B2
公开(公告)日：2019-03-26
申请号：US15033731
申请日：2014-11-03
发明人： Steven L. Colletti , Thomas J. Tucker , David M. Tellers , Boyoung Kim , Rob Burke , Kathleen B. Calati , Matthew G. Stanton , Rubina G. Parmar , Jeffery G. Aaronson , Weimin Wang
IPC分类号： C07K19/00 , C12N15/62 , C12N15/113 , A61K38/14
摘要： Disclosed herein is a peptide containing conjugate comprising (P)c-(L)d-(G)e, wherein P is a peptide and each occurance of P is independently selected from Table 2; L is an optional linker and each occurance of L, if present, is independently selected from Table 3; G is a targeting ligand and each occurance of G is independently selected from Table 4; d is 0, 1, 2, 3, 4, 5 or 6; and each of c and e is independently 1, 2, 3, 4, 5 or 6. The conjugate can be administered to a subject either alone or in combination with a composition comprising R-(L)a-(G)b, wherein R is an oligonucleotide as defined herein, to inhibit expression of a gene of the subject.
-
公开(公告)号：US20170081425A1
公开(公告)日：2017-03-23
申请号：US15033731
申请日：2014-11-03
发明人： Steven L. Colletti , Thomas J. Tucker , David M. Tellers , Boyoung Kim , Rob Burke , Kathleen B. Calati , Matthew G. Stanton , Rubina G. Parmar , Jeffery G. Aaronson , Weimin Wang
IPC分类号： C07K19/00 , C12N15/113
CPC分类号： C07K19/00 , A61K38/14 , C07K2319/00 , C07K2319/01 , C12N15/113 , C12N15/62 , C12N2310/14 , C12N2310/3513
摘要： Disclosed herein is a peptide containing conjugate comprising (P)c-(L)d-(G)e, wherein P is a peptide and each occurance of P is independently selected from Table 2; L is an optional linker and each occurance of L, if present, is independently selected from Table 3; G is a targeting ligand and each occurance of G is independently selected from Table 4; d is 0, 1, 2, 3, 4, 5 or 6; and each of c and e is independently 1, 2, 3, 4, 5 or 6. The conjugate can be administered to a subject either alone or in combination with a composition comprising R-(L)a-(G)b, wherein R is an oligonucleotide as defined herein, to inhibit expression of a gene of the subject.
-
公开(公告)号：US10532068B2
公开(公告)日：2020-01-14
申请号：US15974135
申请日：2018-05-08
发明人： Steven L. Colletti , Thomas J. Tucker , David M. Tellers , Boyoung Kim , Rob Burke , Kathleen B. Calati , Matthew G. Stanton , Rubina G. Parmar , Jeffrey G. Aaronson , Weimin Wang
IPC分类号： C12N15/87 , A61K31/713 , A61K38/10 , A61K38/16 , C12N15/11 , C12N15/113 , A61K31/7125
摘要： Disclosed herein is a method for inhibiting expression of a gene of a subject comprising administering (1) a composition comprising R-(L)a-(G)b; wherein R is an oligonucleotide selected from the group consisting of DNA, RNA, siRNA, and microRNA; L is a linker and each occurrence of L is independently selected from Table 3; G is a targeting ligand and each occurrence of G is independently selected from Table 4; each of a and b is independently 0, 1, 2, 3 or 4; and (2) a composition comprising (P)c-(L)d-(G)e; wherein P is a peptide and each occurrence of P is independently selected from Table 2; L is a linker and each occurrence of L is independently selected from Table 3; G is a targeting ligand and each occurrence of G is independently selected from Table 4; d is 0, 1, 2, 3, 4, 5 or 6; and each of c and e is independently 1, 2, 3, 4, 5 or 6. Compositions in (1) and (2) can be co-administered or sequentially administered.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.019 秒)
